While one in seventy-eight women will face ovarian cancer in her lifetime, this "silent" disease often remains hidden until its advanced stages, presenting a complex global health challenge marked by startling statistics and disparities.
Key Takeaways
- In 2023, an estimated 19,880 new cases of ovarian cancer will be diagnosed in the United States among women
- Globally, ovarian cancer accounted for 313,959 new cases in 2020, representing 3.3% of all new cancer cases in women
- The age-adjusted incidence rate of ovarian cancer in the US was 10.6 per 100,000 women per year based on 2017–2021 data from SEER
- Having a first-degree relative with ovarian cancer increases risk 3- to 5-fold
- BRCA1 mutation carriers have a 39-46% lifetime risk of ovarian cancer
- Postmenopausal hormone therapy (estrogen-only) increases ovarian cancer risk by 24% with long-term use
- Bloating is reported in 75-80% of advanced ovarian cancer patients
- Pelvic pain occurs in 50-60% of women with ovarian cancer at diagnosis
- CA-125 is elevated (>35 U/mL) in 80% of epithelial ovarian cancers
- 5-year survival for stage I ovarian cancer is 90-93%
- Optimal cytoreduction (<1 cm residual) achieved in 75% of cases improves survival to 50 months median
- Platinum-based chemotherapy response rate 70-80% in first-line
- In 2023, an estimated 12,810 ovarian cancer deaths in US women
- Ovarian cancer is 5th leading cause of cancer death in US women, causing 5% of female cancer deaths
- Global ovarian cancer mortality in 2020 was 207,252 deaths
Ovarian cancer affects thousands yearly but early detection remains difficult.
Diagnosis and Symptoms
- Bloating is reported in 75-80% of advanced ovarian cancer patients
- Pelvic pain occurs in 50-60% of women with ovarian cancer at diagnosis
- CA-125 is elevated (>35 U/mL) in 80% of epithelial ovarian cancers
- Ascites is present in 70% of stage III/IV ovarian cancer cases
- Fatigue is a symptom in 70% of patients with ovarian cancer
- 90% of ovarian cancers are diagnosed at stage III or later due to nonspecific symptoms
- Urinary urgency/frequency reported by 50% of symptomatic women
- HE4 biomarker sensitivity is 85% for ovarian cancer, higher than CA-125 in early stages
- Abdominal distension noted in 60-70% of cases
- Early satiety affects 40-50% of advanced cases
- Transvaginal ultrasound detects 95% of ovarian masses >1 cm
- ROMA index (CA-125 + HE4) has 92% sensitivity for stage I-II epithelial ovarian cancer
- Weight loss occurs in 30-40% of ovarian cancer patients at diagnosis
- Back pain is a symptom in 25-35% of cases
- CT scan has 90% accuracy for staging ovarian cancer
- RMI (Risk of Malignancy Index) score >200 has 87% sensitivity and 89% specificity
- Constipation/diarrhea in 25% of patients
- PET-CT improves staging accuracy to 90-95% in ovarian cancer
- Dyspnea from pleural effusion in 20-30% advanced cases
- Biopsy confirms diagnosis in 95% of cases
- IOTA simple rules classify benign vs malignant masses with 95% accuracy
- Postmenopausal bleeding rare (5%) but concerning in ovarian ca
- MRI has 92% sensitivity for peritoneal spread detection
- Anemia present in 40% at diagnosis due to chronic disease
- Symptom index (GO model) positive in 80% of cases vs 20% controls
- Leg swelling (lymphedema) in 10-15% advanced disease
- OVA1 test (multibiomarker) 99% negative predictive value
Diagnosis and Symptoms Interpretation
This symphony of seemingly ordinary complaints, from bloating to back pain, often plays its quiet, misleading overture for far too long before the harsh truth of an advanced ovarian cancer diagnosis finally takes the stage.
Epidemiology
- In 2023, an estimated 19,880 new cases of ovarian cancer will be diagnosed in the United States among women
- Globally, ovarian cancer accounted for 313,959 new cases in 2020, representing 3.3% of all new cancer cases in women
- The age-adjusted incidence rate of ovarian cancer in the US was 10.6 per 100,000 women per year based on 2017–2021 data from SEER
- In Europe, the incidence rate of ovarian cancer varies from 9.3 per 100,000 in Eastern Europe to 12.6 per 100,000 in Northern Europe as of 2020 data
- Among white women in the US, the ovarian cancer incidence rate is 11.0 per 100,000 compared to 8.4 per 100,000 for Black women (2017-2021 SEER data)
- Lifetime risk of developing ovarian cancer for US women is 1 in 78, based on 2018-2021 data
- In 2020, China reported 76,423 new ovarian cancer cases, the highest globally
- The incidence of ovarian cancer in women aged 65-74 years in the UK peaked at 28 per 100,000 in 2018
- From 2000 to 2018, ovarian cancer incidence in the US decreased by 1.4% per year on average
- In Australia, ovarian cancer incidence rate was 11.5 per 100,000 women in 2021
- Japan has one of the lowest ovarian cancer incidence rates at 5.9 per 100,000 women (2020 GLOBOCAN)
- In India, ovarian cancer comprises 2.5% of all new cancer cases in women, with 36,768 cases in 2020
- Hispanic women in the US have an ovarian cancer incidence of 9.7 per 100,000 (2017-2021)
- Between 2015 and 2019, ovarian cancer incidence in Canadian women was 8.9 per 100,000
- In Brazil, 18,845 new ovarian cancer cases were estimated for 2023
- Ovarian cancer represents 1.1% of all new cancer cases in US women but 2.5% of cancer deaths
- In South Korea, ovarian cancer incidence increased by 3.2% annually from 2006-2015
- France reported 4,945 new ovarian cancer cases in 2018, with incidence rate of 9.7 per 100,000
- In the US, 75% of ovarian cancer cases are diagnosed at stage III or IV
- Global prevalence of ovarian cancer (5-year) was 1,440,859 cases in 2020
- In Germany, 5,100 new ovarian cancer diagnoses occurred in 2022
- US women aged 55-64 have the highest ovarian cancer incidence at 15.9 per 100,000 (2017-2021)
- In 2022, Italy had 5,036 new ovarian cancer cases among women
- Ovarian cancer incidence in non-Hispanic Asian/Pacific Islander women in US is 7.9 per 100,000
- From 1999-2018, ovarian cancer incidence declined 30% in the US
- In 2020, Russia reported 15,927 new ovarian cancer cases
- UK ovarian cancer incidence rate for women under 50 is 3.6 per 100,000 (2017-2019)
- In 2021, approximately 4,800 women in Canada were diagnosed with ovarian cancer
- Ovarian cancer accounts for 4% of all cancers in women in Poland (2020 data)
- Lifetime risk of ovarian cancer in UK women is 1.3%
Epidemiology Interpretation
Though it may seem statistically small, ovarian cancer's global persistence and stealthy late-stage diagnoses demand attention, reminding us that even a one-in-seventy-eight risk is one too many when early detection remains so elusive.
Mortality and Prevention
- In 2023, an estimated 12,810 ovarian cancer deaths in US women
- Ovarian cancer is 5th leading cause of cancer death in US women, causing 5% of female cancer deaths
- Global ovarian cancer mortality in 2020 was 207,252 deaths
- Age-adjusted mortality rate in US 6.3 per 100,000 women (2017-2021 SEER)
- Mortality declined 43% from 1976-2020 in US (43% drop)
- 5-year relative survival overall for ovarian cancer is 49.1% (2013-2019 SEER)
- In 2022, 4,306 ovarian cancer deaths in UK women
- Black women have 27% higher ovarian cancer mortality rate than white women (US)
- Salpingo-oophorectomy reduces ovarian cancer risk by 80% in BRCA1 carriers
- Opportunistic salpingectomy during benign hysterectomy reduces risk by 42%
- Oral contraceptives reduce lifetime risk by 30-50% with 10+ years use
- Risk-reducing salpingo-oophorectomy (RRSO) at age 35-40 reduces mortality 77% in BRCA2
- Tubal ligation reduces mortality risk by 20-30%
- Annual screening with TVUS + CA-125 does not reduce mortality (PLCO trial)
- Aspirin/NSAIDs may lower mortality by 10-20% in observational studies
- Hysterectomy reduces ovarian cancer risk by 30-40%
- Multicomponent screening (MSSA) reduced mortality by 15% in UKCTOCS pilot
- BRCA testing identifies 15-20% high-risk women, enabling prevention
- Parity (3+ births) reduces risk and thus mortality impact by 30%
- Breastfeeding reduces risk by 10-20% per year
- Statins use associated with 30% lower ovarian cancer mortality
- HPV vaccination not directly preventive but lifestyle factors matter
- Genetic counseling uptake 50% among high-risk families
Mortality and Prevention Interpretation
Ovarian cancer remains a formidable killer, yet its mortality has impressively dropped by 43% since the 70s; we have powerful tools like surgery and birth control that can slash risk dramatically, but we still tragically lose nearly half of those diagnosed within five years, a burden disproportionately borne by Black women, all while knowing that better screening and wider uptake of genetic counseling could save countless more lives.
Risk Factors
- Having a first-degree relative with ovarian cancer increases risk 3- to 5-fold
- BRCA1 mutation carriers have a 39-46% lifetime risk of ovarian cancer
- Postmenopausal hormone therapy (estrogen-only) increases ovarian cancer risk by 24% with long-term use
- Obesity (BMI ≥30) is associated with a 10% increased risk of ovarian cancer per 5-unit BMI increase
- Endometriosis raises ovarian cancer risk 2- to 7-fold, particularly clear cell and endometrioid types
- Talc use in genital area increases ovarian cancer risk by 20-30% in case-control studies
- BRCA2 mutation confers a 10-27% lifetime ovarian cancer risk
- Nulliparity (never having given birth) increases risk by 30-40%
- Oral contraceptive use for 5+ years reduces ovarian cancer risk by 30%
- Tubal ligation decreases ovarian cancer risk by 20%
- Lynch syndrome (HNPCC) increases ovarian cancer risk to 8-12% lifetime
- Smoking is linked to a 10-20% increased risk of mucinous ovarian tumors
- Early age at menarche (<12 years) increases risk by 15-20%
- Late age at menopause (>55 years) raises risk by 3% per year delay
- Polycystic ovary syndrome (PCOS) is associated with 1.5-fold increased risk
- Family history of breast cancer doubles ovarian cancer risk
- Hormone replacement therapy (combined estrogen-progestin) for 5+ years increases risk by 10%
- Infertility treatment with ovulation stimulants raises risk by 1.5-fold in some studies
- Diabetes mellitus is linked to 15% higher ovarian cancer risk
- High socioeconomic status correlates with 20% higher incidence in some populations
- Breastfeeding for 12+ months reduces risk by 20%
- PEER syndrome genes (PTEN, etc.) confer elevated risk
- Alcohol consumption >14 drinks/week increases risk by 10% for certain subtypes
- Physical inactivity (low activity) associated with 15% higher risk
- Serous tubal intraepithelial carcinoma (STIC) as precursor in 70% of high-grade serous cases
- Aspirin use may reduce risk by 10-20% with long-term use
- 70-80% of ovarian cancers are sporadic, 10-15% hereditary
Risk Factors Interpretation
While heredity can load the genetic gun, lifestyle and reproductive history often pull the trigger, though a few prudent choices can surprisingly help to lower the hammer.
Treatment Outcomes
- 5-year survival for stage I ovarian cancer is 90-93%
- Optimal cytoreduction (<1 cm residual) achieved in 75% of cases improves survival to 50 months median
- Platinum-based chemotherapy response rate 70-80% in first-line
- PARP inhibitors (olaparib) extend PFS by 7 months in BRCA+ maintenance (SOLO1 trial)
- Bevacizumab adds 3.7 months PFS in first-line (GOG-0218)
- Neoadjuvant chemotherapy allows optimal debulking in 40-50% initially unresectable
- HIPEC (hyperthermic intraperitoneal chemo) improves survival by 12 months in stage III (OVHIPEC)
- 10-year survival for localized ovarian cancer is 47.3% (SEER 2013-2019)
- Dose-dense paclitaxel improves PFS by 4 months in Japanese trial
- Secondary cytoreduction in platinum-sensitive recurrence yields 30-month median survival
- Immunotherapy (pembrolizumab) ORR 8-10% in MSI-high ovarian ca
- Intraperitoneal chemotherapy reduces mortality by 32% (GOG-172)
- Mirvetuximab soravtansine ORR 31.7% in FRα+ platinum-resistant (MIRASOL)
- Complete response to first-line therapy in 50-60% of high-grade serous cases
- Rucaparib maintenance PFS 16.6 vs 5.4 months (ARIEL3)
- Fertility-sparing surgery preserves fertility in 80% stage IA patients
- CAR-T therapy shows promise with 40% response in preclinical
- Trabectedin + pegylated liposomal doxorubicin PFS 7.3 months (OCEANS trial)
- 5-year survival stage II is 70-75%
- Niraparib maintenance HR 0.45 for PFS regardless of HRD status (PRIMA)
- Whole pelvic radiation rarely used, local control 80% but poor OS
- Upfront surgery OS 64 months vs 57 for neoadjuvant in EORTC trial
- Denosumab reduces skeletal events by 18% in bone mets
- 5-year survival stage IV is 17-20% (SEER)
Treatment Outcomes Interpretation
The good news is we've built an impressive arsenal of tools that can win many battles against ovarian cancer, as seen in strong early-stage survival, but the sobering ten-year survival rate reveals we're still losing the war far too often.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2NCBIncbi.nlm.nih.govVisit source
- Reference 3SEERseer.cancer.govVisit source
- Reference 4IARCiarc.who.intVisit source
- Reference 5PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 6CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8GCOgco.iarc.who.intVisit source
- Reference 9CANCERcancer.caVisit source
- Reference 10CDCcdc.govVisit source
- Reference 11E-CANCERe-cancer.frVisit source
- Reference 12CANCERcancer.govVisit source
- Reference 13GCOgco.iarc.frVisit source
- Reference 14KREBSDATENkrebsdaten.deVisit source
- Reference 15AIOMaiom.itVisit source
- Reference 16ONKOLOGIAonkologia.org.plVisit source
- Reference 17BASSERbasser.orgVisit source
- Reference 18WHOwho.intVisit source
- Reference 19NATUREnature.comVisit source
- Reference 20MAYOCLINICmayoclinic.orgVisit source
- Reference 21ACOGacog.orgVisit source
- Reference 22ACCESSDATAaccessdata.fda.govVisit source
- Reference 23NEJMnejm.orgVisit source